The Anti-Diabetes Drugs market in Niger is a growing market due to the increasing prevalence of diabetes in the country.
Customer preferences: Niger has a high prevalence of diabetes, with an estimated 5.2% of the population living with the disease. As a result, there is a growing demand for anti-diabetes drugs in the country. However, due to the high poverty levels in Niger, many people cannot afford the high cost of these drugs. This has led to a preference for cheaper, generic versions of the drugs.
Trends in the market: The anti-diabetes drugs market in Niger is primarily driven by the increasing prevalence of diabetes in the country. This has led to a growing demand for drugs such as metformin, sulfonylureas, and insulin. However, due to the high poverty levels in Niger, the market for these drugs is largely dominated by cheaper, generic versions. Additionally, there is a growing trend towards the use of traditional medicine in the treatment of diabetes in Niger.
Local special circumstances: One of the major challenges in the anti-diabetes drugs market in Niger is the lack of access to healthcare. Many people in the country live in rural areas with limited access to healthcare facilities. This has led to a lack of awareness about diabetes and its treatment options. Additionally, there is a lack of trained healthcare professionals in the country, which has further limited access to diabetes treatment.
Underlying macroeconomic factors: Niger is one of the poorest countries in the world, with high levels of poverty and unemployment. This has led to a lack of access to healthcare and a preference for cheaper, generic versions of drugs. Additionally, the country has a high burden of disease, with a high prevalence of infectious diseases such as malaria and tuberculosis. This has led to a limited focus on non-communicable diseases such as diabetes. However, with the increasing prevalence of diabetes in the country, there is a growing need for investment in the anti-diabetes drugs market in Niger.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
